Ticker >

Unjha Formulations share price

Unjha Formulations Ltd.

BSE: 531762 SECTOR: Pharmaceuticals & Drugs  7965   25   1

31.88
+1.51 (4.97%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 31.88

Today's Low

₹ 28.86

52 Week High

₹ 32.73

52 Week Low

₹ 10.55

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

14.28 Cr.

Enterprise Value

14.27 Cr.

No. of Shares

0.45 Cr.

P/E

51.38

P/B

3.06

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  10.44

CASH

0.01 Cr.

DEBT

0 Cr.

Promoter Holding

36.92 %

EPS (TTM)

₹  0.62

Sales Growth

-7.13%

ROE

12.22 %

ROCE

16.76%

Profit Growth

11.88 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-7.13%
3 Year7.45%
5 Year3.09%

Profit Growth

1 Year11.88%
3 Year-2.88%
5 Year1.47%

ROE%

1 Year12.22%
3 Year10.04%
5 Year14.58%

ROCE %

1 Year16.76%
3 Year21.56%
5 Year23.14%

Debt/Equity

0

Price to Cash Flow

-45.4

Interest Cover Ratio

6.69257340241796

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 36.92 0
Dec 2023 36.92 0
Sep 2023 36.92 0
Jun 2023 36.92 0
Mar 2023 36.92 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 21.5641582771303% over the past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 12.4415729501775 days.
  • Company has a healthy liquidity position with current ratio of 2.42007318348144.

 Limitations

  • The company has shown a poor profit growth of -2.87842302901494% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.45356054993629% for the Past 3 years.
  • Company has negative cash flow from operations of -0.3146.
  • The company has a low EBITDA margin of 2.83921376940443% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 2.84 3.76 4.77 5.55 4.44
Total Expenditure 2.95 3.55 4.87 5.14 4.37
Operating Profit -0.11 0.21 -0.1 0.41 0.07
Other Income 0 -0.01 0 0 0
Interest 0.05 0.02 0 0 0.05
Depreciation 0.02 0 0.02 0.02 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.18 0.18 -0.12 0.39 0
Tax 0.05 0 0 0 0.17
Profit After Tax -0.22 0.18 -0.12 0.39 -0.18
Adjusted EPS (Rs) -0.5 0.41 -0.26 0.87 -0.39

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 11.42 10.6 9.96 14.16 13.15
Total Expenditure 11.12 10.35 9.59 13.84 12.72
Operating Profit 0.3 0.25 0.36 0.32 0.43
Other Income 0.1 0.26 0.22 0.19 0.03
Interest 0.01 0.12 0.17 0.13 0.06
Depreciation 0.09 0.08 0.08 0.08 0.08
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.3 0.31 0.33 0.3 0.33
Tax 0 0 0.23 0.05 0.05
Net Profit 0.3 0.31 0.1 0.25 0.28
Adjusted EPS (Rs.) 0.67 0.69 0.23 0.56 0.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 4.48 4.48 4.48 4.48 4.48
Total Reserves -2.97 -2.67 -2.56 -2.31 -2.03
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 2.15 1.9 1.61 1.28 0.96
Total Liabilities 3.65 3.72 3.53 3.45 3.41
Assets
Net Block 1.12 1.14 1.12 1.07 1.1
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 2.54 2.57 2.4 2.38 2.31
Total Assets 3.65 3.72 3.53 3.45 3.41
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0.3 0.31 0.1 0.25 0.28
Adjustment 0.1 0.2 0.25 0.21 0.13
Changes in Assets & Liabilities -0.51 0.01 -0.89 -0.05 -0.67
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.12 0.39 -0.7 0.28 -0.31
Investing Cash Flow 0.04 -0.1 -0.06 -0.02 -0.1
Financing Cash Flow 0.23 0 0 0 0
Net Cash Flow 0.16 0.29 -0.77 0.26 -0.42

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 36.92 36.92 36.92 36.92 36.92
jashodaben shambhubhai pa... 16.51 16.51 16.51 16.51 16.51
krutiben mayankkumar pate... 14.89 14.89 14.89 14.89 14.89
neenaben urveshkumar pate... 1.90 1.90 1.90 - 1.90
urveshkumar shambhubhai p... 3.62 3.62 3.62 3.62 3.62
neeneben urveshkumar pate... - - - 1.90 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 63.08 63.08 63.08 63.08 63.08
deep mayankbhai patel 1.29 1.29 1.16 1.29 1.29
esha mayank patel 1.35 1.35 1.60 - 1.60
jatinkumar babulal patel 1.06 1.06 1.06 1.06 1.06
manish patel - - - 1.13 1.25
narveer yadav 1.16 1.17 1.17 1.17 1.17
dheeraj kumar lohia - - - 1.15 -
esha mayank patel - - - 1.60 -
dheeraj kumar lohia 1.15 1.15 1.15 - -
kailashben ashokkumar pat... - 2.01 - - -
kailashban ashokkumar pat... 2.18 - - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Unjha Formulations - Quaterly Results17 May 2024, 3:18PM Unjha Formulations - Quaterly Results17 May 2024, 3:18PM Unjha Formulations - Quaterly Results17 May 2024, 3:18PM Unjha Formulations informs about board meeting8 May 2024, 5:20PM Unjha Formulations - Quaterly Results29 Jan 2024, 2:06PM Unjha Formulations - Quaterly Results29 Jan 2024, 2:06PM Unjha Formulations - Quaterly Results29 Jan 2024, 2:06PM Unjha Formulations - Quaterly Results4 Aug 2023, 2:31PM Unjha Formulations - Quaterly Results4 Aug 2023, 2:31PM Unjha Formulations - Quaterly Results4 Aug 2023, 2:31PM Unjha Formulations - Quaterly Results10 May 2023, 3:01PM Unjha Formulations - Quaterly Results10 May 2023, 3:01PM Unjha Formulations - Quaterly Results10 May 2023, 3:01PM Unjha Formulations informs about change in promoters shareholding14 Mar 2023, 1:00PM Unjha Formulations - Quaterly Results10 Feb 2023, 1:20PM Unjha Formulations - Quaterly Results10 Feb 2023, 1:20PM Unjha Formulations - Quaterly Results10 Feb 2023, 1:20PM Unjha Formulations - Quaterly Results10 Nov 2022, 1:10PM Unjha Formulations - Quaterly Results10 Nov 2022, 1:10PM Unjha Formulations - Quaterly Results4 Aug 2022, 1:29PM Unjha Formulations - Quaterly Results4 Aug 2022, 1:29PM Unjha Formulations - Quaterly Results4 Aug 2022, 1:29PM Unjha Formulations informs about book closure13 Jul 2022, 4:08PM Unjha Formulations - Quaterly Results2 May 2022, 2:40PM Unjha Formulations - Quaterly Results2 May 2022, 2:40PM Unjha Formulations - Quaterly Results2 May 2022, 2:40PM Unjha Formulations informs about board meeting intimation 18 Apr 2022, 4:47PM Unjha Formulations - Quaterly Results4 Feb 2022, 1:24PM Unjha Formulations - Quaterly Results4 Feb 2022, 1:24PM Unjha Formulations - Quaterly Results4 Feb 2022, 1:24PM Unjha Formulations informs about filing of distribution schedule28 Aug 2021, 2:35PM Unjha Formulations informs about outcome of board meeting23 Mar 2021, 3:23PM Unjha Formulations informs about board meeting17 Mar 2021, 11:09AM Unjha Formulations informs about newspaper publication10 Nov 2020, 11:09AM

Unjha Formulations Stock Price Analysis and Quick Research Report. Is Unjha Formulations an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Unjha Formulations and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Unjha Formulations cash from the operating activity was Rs -0.3146 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Unjha Formulations has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Unjha Formulations , the EPS growth was 11.8811881188119 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Unjha Formulations has OPM of 3.29413016869777 % which is a bad sign for profitability.
     
  • ROE: Unjha Formulations have a average ROE of 12.2183296570218 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Unjha Formulations is Rs 31.88. One can use valuation calculators of ticker to know if Unjha Formulations share price is undervalued or overvalued.
Last Updated on:
Brief about Unjha Formulations
X